UBS has upgraded Max Healthcare to a 'buy' rating, raising the target price to Rs 1,200 from Rs 610, citing efficient execution in bed additions and profitable acquisitions. The brokerage anticipates the company's bed capacity will double in three years, highlighting strong occupancy rates and an asset-light model that provides a competitive edge. Despite a recent 13% stock decline, UBS views this as an attractive entry point, noting minimal impact from insurance price negotiations on larger chains like Max.